MSCT联合血清PRSS2、EFNA1诊断胃癌患者淋巴结转移的价值

doi:10.3760/cma.j.cn441417-20241223-17001

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (17): 2818-2822.DOI: 10.3760/cma.j.cn441417-20241223-17001

• 胃肠道疾病专题 • 下一篇

MSCT联合血清PRSS2、EFNA1诊断胃癌患者淋巴结转移的价值

孙利慧¹ 李亚俊² 陈建婷³ 王军艳³ 张鸣³

¹西安高新医院消化内科，西安 710075；²宁夏医科大学总医院消化内科，银川 750000；³西安医学院第二附属医院消化内科，西安 710000

收稿日期:2024-12-23 出版日期:2025-09-01 发布日期:2025-09-23
通讯作者: Email：zhang_ming1122@163.com
基金资助:
宁夏自然科学基金（2022AAC03525）

The value of MSCT combined with serum PRSS2 and EFNA1 in diagnosing lymph node metastasis in patients with gastric cancer

Sun Lihui¹, Li Yajun², Chen Jianting³, Wang Junyan³, Zhang Ming³

¹Department of Gastroenterology, Xi'an Gaoxin Hospital, Xi'an 710075, China; ²Department of Gastroenterology, General Hospital of Ningxia Medical University, Yinchuan 750000, China; ³Department of Gastroenterology, The Second Affiliated Hospital of Xi'an Medical University, Xi'an 710000, China

Received:2024-12-23 Online:2025-09-01 Published:2025-09-23
Contact: Zhang Ming, Email: zhang_ming1122@163.com
Supported by:
Ningxia Natural Science Foundation (2022AAC03525)

摘要/Abstract

摘要：

目的　探讨多层螺旋计算机断层扫描（MSCT）联合血清丝氨酸蛋白酶2（PRSS2）、肝配蛋白A1（EFNA1）诊断胃癌患者淋巴结转移的价值。方法　选取2021年2月至2024年8月西安高新医院收治的124例胃癌患者作为研究对象，其中男74例，女50例；年龄34～73（55.33±5.28）岁。所有患者均行MSCT检查、血清PRSS2和EFNA1检测、病理检查。根据病理检查结果，将患者分为未转移组（59例）和转移组（65例）。比较两组MSCT参数［血容量（BV）、血流量（BF）、表面通透性（PS）、对比剂平均通过时间（MTT）］、血清PRSS2和EFNA1。采用独立样本t检验、Mann-Whitney U检验进行统计学分析。采用受试者操作特征曲线（ROC）分析MSCT参数联合血清PRSS2、EFNA1诊断胃癌患者淋巴结转移的价值。结果　两组BV比较，差异无统计学意义（P>0.05）；转移组BF、PS、MTT均高于未转移组［（92.66±27.82）ml/（100 mg·min）比（73.42±20.86）ml/（100 mg·min）、（9.64±2.78）ml/（100 mg·min）比（7.61±1.18）ml/（100 mg·min）、（28.54±5.28）s比（22.67±3.14）s］（均P<0.05）。转移组血清PRSS2、EFNA1均高于未转移组［3.65（2.87，5.22）比2.12（1.82，2.56）、1.63（1.30，1.77）比1.15（0.95，1.32）］（均P<0.05）。ROC显示，MSCT参数（BF、PS、MTT）联合血清PRSS2、EFNA1诊断胃癌患者淋巴结转移的灵敏度高于单独诊断，曲线下面积高于单独诊断（均P<0.05），特异度与单独诊断基本一致。结论　MSCT参数（BF、PS、MTT）与血清PRSS2、EFNA1均有助于临床诊断胃癌患者淋巴结转移，且联合诊断价值更高。

关键词:

胃癌, 多层螺旋计算机断层扫描, 丝氨酸蛋白酶2, 肝配蛋白A1, 淋巴结转移

Abstract:

Objective　To explore the value of multi-slice spiral computed tomography (MSCT) combined with serum serine protease 2 (PRSS2) and ephrin A1 (EFNA1) in diagnosing lymph node metastasis in patients with gastric cancer. Methods　A total of 124 patients with gastric cancer who were admitted to Xi'an Gaoxin Hospital from February 2021 to August 2024 were selected as the research subjects. Among them, 74 were male and 50 were female; the age ranged from 34 to 73 (55.33±5.28) years old. All patients underwent MSCT examination, serum PRSS2 and EFNA1 tests, and pathological examination. Based on the pathological examination results, the patients were divided into the non-metastasis group (59 cases) and the metastasis group (65 cases). The parameters of MSCT [blood volume (BV), blood flow (BF), surface permeability (PS), and mean transit time of contrast agent (MTT)] were compared between the two groups, as well as serum PRSS2 and EFNA1. Independent sample t test, and Mann-Whitney U test were used for statistical analysis. The value of combining MSCT parameters with serum PRSS2 and EFNA1 in diagnosing lymph node metastasis in patients with gastric cancer was analyzed using the receiver operating characteristic curve (ROC). Results　Comparison between the two groups of BV showed no statistically significant difference (P>0.05); in the metastasis group, BF, PS, and MTT were all higher than those in the non-metastasis group [(92.66±27.82) ml/(100 mg·min) vs. (73.42±20.86) ml/(100 mg·min), (9.64±2.78) ml/(100 mg·min) vs. (7.61±1.18) ml/(100 mg·min), (28.54±5.28) s vs. (22.67±3.14) s] (all P<0.05). The serum levels of PRSS2 and EFNA1 in the metastasis group were higher than those in the non-metastasis group [3.65 (2.87, 5.22) vs. 2.12 (1.82, 2.56), 1.63 (1.30, 1.77) vs. 1.15 (0.95, 1.32)] (both P<0.05). The ROC curve showed that the combination of MSCT parameters (BF, PS, MTT) and serum PRSS2, EFNA1 for diagnosing lymph node metastasis in gastric cancer patients had a higher sensitivity than single diagnosis, and the area under the curve was higher than that of single diagnosis (all P<0.05), while the specificity was basically consistent with that of single diagnosis. Conclusion　The MSCT parameters (BF, PS, MTT) and serum PRSS2, EFNA1 are all helpful for the clinical diagnosis of lymph node metastasis in patients with gastric cancer, and their combined diagnosis has a higher value.

Key words:

Gastric cancer, Multi-slice spiral computed tomography, Serine protease 2, Ephrin A1, Lymph node metastasis

孙利慧李亚俊陈建婷王军艳张鸣.

MSCT联合血清PRSS2、EFNA1诊断胃癌患者淋巴结转移的价值 [J]. 国际医药卫生导报, 2025, 31(17): 2818-2822.

Sun Lihui, Li Yajun, Chen Jianting, Wang Junyan, Zhang Ming.

The value of MSCT combined with serum PRSS2 and EFNA1 in diagnosing lymph node metastasis in patients with gastric cancer [J]. International Medicine and Health Guidance News, 2025, 31(17): 2818-2822.

参考文献

[1] Zhu KG, Yang J, Zhu Y, et al. The microprotein encoded by exosomal lncAKR1C2 promotes gastric cancer lymph node metastasis by regulating fatty acid metabolism[J]. Cell Death Dis, 2023, 14(10):708. DOI:10.1038/s41419-023-06220-1.
[2] 罗韵,徐国亭.丙泊酚泵注下的全凭静脉麻醉与吸入麻醉在胃癌根治术全麻中的应用效果[J].国际医药卫生导报,2023,29(11):1541-1545. DOI:10.3760/cma.j.issn.1007-1245.2023.11.014.
[3] Huang J, Wang X, Wen J, et al. Gastric cancer cell-originated small extracellular vesicle induces metabolic reprogramming of BM-MSCs through ERK-PPARγ-CPT1A signaling to potentiate lymphatic metastasis[J]. Cancer Cell Int, 2023, 23(1):87. DOI:10.1186/s12935-023-02935-5.
[4] 韩超,陈新晖,赵宝琼,等.MSCT用于胃癌淋巴结转移早期诊断的临床价值[J].海南医学,2021,32(6):746-749. DOI:10.3969/j.issn.1003-6350.2021.06.018.
[5] 蒋亚兰,张越,张晓,等.多层螺旋CT在胃癌转移性淋巴结分期中的诊断价值研究[J].中国医学装备,2022,19(10):28-32. DOI:10.3969/J.ISSN.1672-8270.2022.10.007.
[6] Sui L, Wang S, Ganguly D, et al. PRSS2 remodels the tumor microenvironment via repression of Tsp1 to stimulate tumor growth and progression[J]. Nat Commun, 2022, 13(1):7959. DOI:10.1038/s41467-022-35649-9.
[7] Chu LY, Huang BL, Huang XC, et al. EFNA1 in gastrointestinal cancer: expression, regulation and clinical significance[J]. World J Gastrointest Oncol, 2022, 14(5):973-988. DOI:10.4251/wjgo.v14.i5.973.
[8] 中华人民共和国国家卫生和计划生育委员会.胃癌规范化诊疗指南(试行)[J/OL].中国医学前沿杂志(电子版),2013,5(8):56-63[2024-11-20].https://d.wanfangdata.com.cn/periodical/ChVQZXJpb2RpY2FsQ0hJMjAyNTA2MjISEXpneXhxeXp6MjAxMzA4MDEyGghpcXBld2hqNg%3D%3D. DOI:10.3969/j.issn.1674-7372.2013.08.012.
[9] Shen X, Kong S, Ma S, et al. Hsa_circ_0000437 promotes pathogenesis of gastric cancer and lymph node metastasis[J]. Oncogene, 2022, 41(42):4724-4735. DOI:10.1038/s41388-022-02449-w.
[10] Pang S, Wang W, Zhou J, et al. Inverse association between age and risk of lymph node metastasis in patients with early gastric cancer: a surveillance, epidemiology, and end results analysis[J]. J Cancer, 2024, 15(9):2829-2836. DOI:10.7150/jca.94542.
[11] 柯楠,刘凯,牟东景,等. MSCT联合血清sB7-H4、YKL-40诊断胃癌淋巴结转移的临床价值[J].河北医药,2024,46(9):1345-1348. DOI:10.3969/j.issn.1002-7386.2024.09.013.
[12] 李扬,孙继锋,郭华.MSCT联合血清VEGF-C、Ang-2在胃癌淋巴结转移诊断中的应用[J].中国CT和MRI杂志,2022,20(10):120-122. DOI:10.3969/j.issn.1672-5131.2022.10.046.
[13] 张云云.MSCT灌注成像参数与胃癌患者血流动力学指标及临床病理特征的关系[J].影像研究与医学应用,2024,8(4):66-68.DOI:10.3969/j.issn.2096-3807.2024.04.021.
[14] 胡国权,郝建成,范元军,等.多层螺旋CT对可切除性胃癌转移性淋巴结及N分期的诊断价值研究[J].中国普外基础与临床杂志,2022,29(4):527-531. DOI:10.7507/1007-9424.202108097.
[15] Zou WB, Cooper DN, Masson E, et al. Trypsinogen (PRSS1 and PRSS2) gene dosage correlates with pancreatitis risk across genetic and transgenic studies: a systematic review and re-analysis[J]. Hum Genet, 2022, 141(8):1327-1338. DOI:10.1007/s00439-022-02436-x.
[16] Qin H, Zhang S, Shen L, et al. High expression of serine protease 2 (PRSS2) associated with invasion, metastasis, and proliferation in gastric cancer[J]. Aging (Albany NY), 2023, 15(7):2473-2484. DOI:10.18632/aging.204604.
[17] Wang F, Yi J, Chen Y, et al. PRSS2 regulates EMT and metastasis via MMP-9 in gastric cancer[J]. Acta Histochem, 2023, 125(6):152071. DOI:10.1016/j.acthis.2023.152071.
[18] Hao YP, Wang WY, Qiao Q, et al. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma[J]. Medicine (Baltimore), 2021, 100(22):e26188. DOI:10.1097/MD.0000000000026188.
[19] Joshi N, Bhat F, Bellad A, et al. Urinary proteomics for discovery of gastric cancer biomarkers to enable precision clinical oncology[J]. OMICS, 2023, 27(8):361-371. DOI:10.1089/omi.2023.0077.
[20] Chu LY, Wu FC, Guo HP, et al. Combined detection of serum EFNA1 and MMP13 as diagnostic biomarker for gastric cancer[J]. Sci Rep, 2024, 14(1):15957. DOI:10.1038/s41598-024-65839-y.
[21] Wu Y, Du Z, Mou J, et al. The functions of EphA1 receptor tyrosine kinase in several tumors[J]. curr med chem, 2023, 30(20):2340-2353. DOI:10.2174/0929867329666220820125638.
[22] 沈朝军,姜研,沈艳,等.MSCT三期动态增强扫描在胃癌术前分期以及淋巴结转移诊断中的应用价值[J].蚌埠医学院学报,2021,46(11):1595-1599. DOI:10.13898/j.cnki.issn.1000-2200.2021.11.025.

MSCT联合血清PRSS2、EFNA1诊断胃癌患者淋巴结转移的价值

The value of MSCT combined with serum PRSS2 and EFNA1 in diagnosing lymph node metastasis in patients with gastric cancer

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 7

编辑推荐

Metrics

[1]	邵远王志斌阚炳华. 自动乳腺容积成像联合miR-22-3p、PDGF对乳腺癌患者淋巴结转移及预后的关系 [J]. 国际医药卫生导报, 2025, 31(8): 1244-1249.
[2]	罗振峰赵谦封辉. 甲状腺微小乳头状癌颈部中央区淋巴结转移的临床特征及危险因素分析 [J]. 国际医药卫生导报, 2025, 31(8): 1358-1363.
[3]	葛强李建宜闫晓红. MSCT检查联合血清CA125、SCC、ProGRP、NSE诊断肺癌的准确性 [J]. 国际医药卫生导报, 2025, 31(5): 810-814.
[4]	赵莉马居里苏衍进袁秀丽. 分化型甲状腺癌患者二次手术后继发性甲减的影响因素 [J]. 国际医药卫生导报, 2025, 31(4): 645-649.
[5]	折文利徐鑫利李彦婷李新. 超声及临床病理特征对甲状腺乳头状癌Delphian淋巴结转移的诊断价值 [J]. 国际医药卫生导报, 2024, 30(17): 2951-2956.
[6]	何学学杨宁折慧. MASP-2和补体因子H在自身免疫性肝炎患者中的表达意义 [J]. 国际医药卫生导报, 2024, 30(14): 2375-2379.
[7]	李贤浩吕文强曾贵青韦武芝. PET-CT在非小细胞肺癌术前区域淋巴结转移评估中的应用价值 [J]. 国际医药卫生导报, 2023, 29(15): 2155-2157.